EP79 – Risk Assessment Systems in Differentiated Thyroid Cancer

     

    Durán Poveda, Manuel1; Guadarrama González, F. Javier2; Ferrero Herrero, Eduardo2;
    1 Department of Surgery, Juan Carlos I Hospital, Móstoles, Madrid, Spain
    2 Department of Surgery, 12 de Octubre University Hospital, Madrid, Spain

     

    Background: Many risk factors have been identified in differentiated thyroid cancer; with these in mind, some prognostic scores have been designed to assess risk of recurrence and survival.

    Objective
    : To evaluate usefulness of different methods of risk assignment in differentiated thyroid cancer in surgical patients

    Material and Methods: Retrospective review of 232 patients with differentiated thyroid cancer treated in our hospital from 1991 to 2014, staged by pTNM (7th edition, 2010) and followed for 1 to 23 years. Risk groups were assigned by MACIS, AGES, AMES and ATA systems. Correlation of recurrences and survival was carried out according to score or risk assignment. Curves were calculated for disease-free interval, mortality, related and not related to the thyroid tumor, age, sex, histological type, grading, Kaplan-Meyer actuarial survival, statistical significance and Wilcoxon test for comparison of pathological data.

    Results
    : Overall survival was 96%, 93% and 84% at 5, 10 and 20 years, and a median disease-free survival of 18,5 years (range 1-20 years) with a mean survival of 16,019 years. Total mortality was 6.46% and tumor-related mortality 2.58 %. In multivariate analysis, the variables related to prognosis with respect to overall survival were: tumor size> 4 cm., Tall-cell histologic type, tumor grade, lymph node involvement, and soft tissue and vascular invasion.

    Conclusion: MACIS, AGES and AMES systems are useful for risk assessment in our population, but it is necessary to become familiar with its use to select the extent of therapy in each case.

     

    References:

    1. Edge S.B, Byrd D.R,  Comton C.C, Fritz A.G, Greene F.L, Trotti A. AJCC Cancer Staging Manual 7th Edition, 2010. ISBN 978-0-387-88440-0.
    2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma. Development of a reliable prognostic scoring system in a cohort of 1.779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050-1058.
    3. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088-1095.
    4. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-953.
      American Thyroid Association (ATA) Management Guidelines for Adults Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Haugen A. et al., Thyroid 2015. 10-1089

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    Steering Committee
    Rocco Bellatone, MD, Co-Chair
    Celestino Lombardi, MD, Co-Chair
    Gregory Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD